Literature DB >> 29734306

Allogene and Celularity move CAR-T therapy off the shelf.

Cormac Sheridan.   

Abstract

Year:  2018        PMID： 29734306     DOI： 10.1038/nbt0518-375

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Off-the-shelf CAR-T therapy induces remission in child with ALL.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2016-01       Impact factor: 54.908

2.  Enzyme loading of erythrocytes.

Authors:  G M Ihler; R H Glew; F W Schnure
Journal:  Proc Natl Acad Sci U S A       Date:  1973-09       Impact factor: 11.205

3.  Epic $12 billion deal and FDA's approval raise CAR-T to new heights.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-10-11       Impact factor: 54.908

4.  An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

Authors:  Lydia Lee; Benjamin Draper; Neil Chaplin; Brian Philip; Melody Chin; Daria Galas-Filipowicz; Shimobi Onuoha; Simon Thomas; Vania Baldan; Reyisa Bughda; Paul Maciocia; Eva Kokalaki; Margarida P Neves; Dominic Patel; Manuel Rodriguez-Justo; James Francis; Kwee Yong; Martin Pule
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

5.  Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.

Authors:  Kole T Roybal; Levi J Rupp; Leonardo Morsut; Whitney J Walker; Krista A McNally; Jason S Park; Wendell A Lim
Journal:  Cell       Date:  2016-01-28       Impact factor: 41.582

6.  Remote control of therapeutic T cells through a small molecule-gated chimeric receptor.

Authors:  Chia-Yung Wu; Kole T Roybal; Elias M Puchner; James Onuffer; Wendell A Lim
Journal:  Science       Date:  2015-09-24       Impact factor: 47.728
  6 in total
  2 in total

Review 1.  Natural Killer T Cells and Mucosal-Associated Invariant T Cells in Lung Infections.

Authors:  François Trottein; Christophe Paget
Journal:  Front Immunol       Date:  2018-08-02       Impact factor: 7.561

Review 2.  Emerging treatment options for patients with p53-pathway-deficient CLL.

Authors:  Marisa J L Aitken; Hun J Lee; Sean M Post
Journal:  Ther Adv Hematol       Date:  2019-12-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.